A Study of Intravenous Tamiflu (Oseltamivir) in Children With Influenza
NCT ID: NCT01033734
Last Updated: 2016-08-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
8 participants
INTERVENTIONAL
2010-12-31
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Intravenous Oseltamivir [Tamiflu] in Infants With Influenza
NCT01053663
Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza
NCT00391768
A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection
NCT00988325
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
NCT01050257
A Study of Tamiflu (Oseltamivir) for Seasonal Prophylaxis of Influenza in Children.
NCT00412555
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single arm
oseltamivir [Tamiflu]
5-day course (10 doses), intravenous administration, may be switched to oral administration at the discretion of the investigator; up to 5 additional days of treatment possible.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
oseltamivir [Tamiflu]
5-day course (10 doses), intravenous administration, may be switched to oral administration at the discretion of the investigator; up to 5 additional days of treatment possible.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosis of influenza
* duration of influenza symptoms \</=96 hours prior to first dose of study drug
Exclusion Criteria
* patients taking probenecid within 1 week prior to first dose of study drug
1 Year
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Los Angeles, California, United States
Oakland, California, United States
Aurora, Colorado, United States
Wilmington, Delaware, United States
Jacksonville, Florida, United States
Chicago, Illinois, United States
South Bend, Indiana, United States
Wichita, Kansas, United States
Louisville, Kentucky, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Springfield, Massachusetts, United States
Detroit, Michigan, United States
Duluth, Minnesota, United States
Omaha, Nebraska, United States
Morristown, New Jersey, United States
Brooklyn, New York, United States
New York, New York, United States
Stony Brook, New York, United States
Syracuse, New York, United States
The Bronx, New York, United States
Durham, North Carolina, United States
Raleigh, North Carolina, United States
Akron, Ohio, United States
Cleveland, Ohio, United States
Dayton, Ohio, United States
Toledo, Ohio, United States
Toledo, Ohio, United States
Oklahoma City, Oklahoma, United States
Tyrone, Pennsylvania, United States
Providence, Rhode Island, United States
Charleston, South Carolina, United States
Houston, Texas, United States
Richmond, Virginia, United States
Madison, Wisconsin, United States
Petah Tikva, , Israel
Beirut, , Lebanon
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Munoz FM, Anderson EJ, Deville JG, Clinch B, Kamal MA. Pharmacokinetics and safety of intravenous oseltamivir in infants and children in open-label studies. Int J Clin Pharmacol Ther. 2015 Jul;53(7):531-40. doi: 10.5414/CP202307.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NP25139
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.